FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304694148> ?p ?o ?g. }

• W4304694148 abstract "With the success of chimeric antigen receptor-modified (CAR) T-cell therapy for relapsed/refractory (r/r) B-cell malignancies, severe complications after CAR T-cell infusion have emerged as nonnegligible prognosis-related factors. However, the prognosis of patients with CAR T-cell-related hyperferritinaemia (HFA) is unclear. We report the efficacy and safety of CAR T-cell therapy in 16 r/r B-cell malignancy patients with CAR T-cell-related HFA. The rates of serum ferritin levels above 10,000 ng/ml during CAR T-cell therapy were 6.2% and 14.3% in B-cell non-Hodgkin’s lymphoma (B-NHL) and acute B lymphocyte leukemia (B-ALL), respectively. These patients were characterized by an extremely high tumor burden and a high rate of extranodal involvement. In lymphoma, the complete remission (CR) rate was 37.5% (3/8), which was lower than that in the control group with the lowest value of ferritin (CR was 87.5% (7/8), P=0.0406), and it could also be seen that the OS of the control group (1-year OS rate 100%) had a better trend than HFA group (1-year OS rate 50%). In the B-ALL patients, the OS of the control group (1-year OS rate 100%) was higher than HFA group (1-year OS rate 45%, P=0.0189), although there was no significant difference in CR rate. High-grade CRS (≥3) occurred in 56.25% of the patients, and the mortality rate was 56.25%, which was significantly higher than control group (12.5% and 12.5%, P=0.009). The peak serum ferritin level in the patients who died of CRS was significantly higher than others (P=0.0168). Regardless of whether the CAR T-related MAS diagnostic criteria were met, there was no significant difference in ORR and OS in HFA group, however patients with MAS showed a higher rate of high-grade CRS. Interestingly, in our study, glucocorticoid intervention in HFA group showed little impact on expansion of CAR-T cells, whether compared with control group or compared within HFA group by dividing patients into high and low dosage subgroups based on the median dose of glucocorticoid. High mortality was observed in patients with CAR T-cell-related HFA. Early glucocorticoid intervention might be worth trying to improve the safety of CAR T therapy in these patients." @default.
• W4304694148 created "2022-10-12" @default.
• W4304694148 creator A5002075935 @default.
• W4304694148 creator A5013303826 @default.
• W4304694148 creator A5022798213 @default.
• W4304694148 creator A5024747900 @default.
• W4304694148 creator A5036882735 @default.
• W4304694148 creator A5052304130 @default.
• W4304694148 creator A5054659867 @default.
• W4304694148 creator A5060747632 @default.
• W4304694148 date "2022-10-12" @default.
• W4304694148 modified "2023-10-18" @default.
• W4304694148 title "Clinical characteristics and prognosis of 16 relapsed/refractory B-cell malignancy patients with CAR T-cell-related hyperferritinaemia" @default.
• W4304694148 cites W1784814409 @default.
• W4304694148 cites W2051898696 @default.
• W4304694148 cites W2119147717 @default.
• W4304694148 cites W2125270092 @default.
• W4304694148 cites W2340435799 @default.
• W4304694148 cites W2417246715 @default.
• W4304694148 cites W2519710256 @default.
• W4304694148 cites W2554186605 @default.
• W4304694148 cites W2598700764 @default.
• W4304694148 cites W2673558759 @default.
• W4304694148 cites W2754562068 @default.
• W4304694148 cites W2773804840 @default.
• W4304694148 cites W2787621143 @default.
• W4304694148 cites W2803430447 @default.
• W4304694148 cites W2808005169 @default.
• W4304694148 cites W2885964573 @default.
• W4304694148 cites W2903062212 @default.
• W4304694148 cites W2906344733 @default.
• W4304694148 cites W2917676884 @default.
• W4304694148 cites W2936293163 @default.
• W4304694148 cites W2980542859 @default.
• W4304694148 cites W2982584762 @default.
• W4304694148 cites W2985291222 @default.
• W4304694148 cites W3002263815 @default.
• W4304694148 cites W3006385788 @default.
• W4304694148 cites W3008376116 @default.
• W4304694148 cites W3014700159 @default.
• W4304694148 cites W3016233874 @default.
• W4304694148 cites W3040926950 @default.
• W4304694148 cites W3044532926 @default.
• W4304694148 cites W3047493249 @default.
• W4304694148 cites W3082855561 @default.
• W4304694148 cites W3093246259 @default.
• W4304694148 cites W3108929845 @default.
• W4304694148 cites W3122968352 @default.
• W4304694148 cites W3128956257 @default.
• W4304694148 cites W3186991133 @default.
• W4304694148 cites W3211929629 @default.
• W4304694148 cites W4234603135 @default.
• W4304694148 doi "https://doi.org/10.3389/fonc.2022.912689" @default.
• W4304694148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36313658" @default.
• W4304694148 hasPublicationYear "2022" @default.
• W4304694148 type Work @default.
• W4304694148 citedByCount "0" @default.
• W4304694148 crossrefType "journal-article" @default.
• W4304694148 hasAuthorship W4304694148A5002075935 @default.
• W4304694148 hasAuthorship W4304694148A5013303826 @default.
• W4304694148 hasAuthorship W4304694148A5022798213 @default.
• W4304694148 hasAuthorship W4304694148A5024747900 @default.
• W4304694148 hasAuthorship W4304694148A5036882735 @default.
• W4304694148 hasAuthorship W4304694148A5052304130 @default.
• W4304694148 hasAuthorship W4304694148A5054659867 @default.
• W4304694148 hasAuthorship W4304694148A5060747632 @default.
• W4304694148 hasBestOaLocation W43046941481 @default.
• W4304694148 hasConcept C121608353 @default.
• W4304694148 hasConcept C126322002 @default.
• W4304694148 hasConcept C142424586 @default.
• W4304694148 hasConcept C143998085 @default.
• W4304694148 hasConcept C159654299 @default.
• W4304694148 hasConcept C203014093 @default.
• W4304694148 hasConcept C2776283816 @default.
• W4304694148 hasConcept C2777257650 @default.
• W4304694148 hasConcept C2777701055 @default.
• W4304694148 hasConcept C2778453870 @default.
• W4304694148 hasConcept C2779338263 @default.
• W4304694148 hasConcept C2779399171 @default.
• W4304694148 hasConcept C3875195 @default.
• W4304694148 hasConcept C71924100 @default.
• W4304694148 hasConcept C86803240 @default.
• W4304694148 hasConcept C87355193 @default.
• W4304694148 hasConcept C90924648 @default.
• W4304694148 hasConceptScore W4304694148C121608353 @default.
• W4304694148 hasConceptScore W4304694148C126322002 @default.
• W4304694148 hasConceptScore W4304694148C142424586 @default.
• W4304694148 hasConceptScore W4304694148C143998085 @default.
• W4304694148 hasConceptScore W4304694148C159654299 @default.
• W4304694148 hasConceptScore W4304694148C203014093 @default.
• W4304694148 hasConceptScore W4304694148C2776283816 @default.
• W4304694148 hasConceptScore W4304694148C2777257650 @default.
• W4304694148 hasConceptScore W4304694148C2777701055 @default.
• W4304694148 hasConceptScore W4304694148C2778453870 @default.
• W4304694148 hasConceptScore W4304694148C2779338263 @default.
• W4304694148 hasConceptScore W4304694148C2779399171 @default.
• W4304694148 hasConceptScore W4304694148C3875195 @default.
• W4304694148 hasConceptScore W4304694148C71924100 @default.
• W4304694148 hasConceptScore W4304694148C86803240 @default.
• W4304694148 hasConceptScore W4304694148C87355193 @default.

• next